Pre-IPO TransThera Sciences (Nanjing) - Insights on the Industry, the Business and the Concerns
212 Views06 Oct 2021 09:02
This article mainly analyzed TransThera in terms of the industry characteristics of small molecule drug market, candidates in the pipeline (TT-00420, TT-00434, TT-01488 and others), and the concerns.
SUMMARY
(Sign Up to Access)Get started on the Smartkarma Research Network with a complimentary Preview Pass to:
- Unlock all research summaries
- Follow top, independent analysts
- Receive personalised alerts and emails
- Access Briefings, Analytics, and Events
Upgrade anytime to our paid plans for full-length research, real-time analyst discussions, and more.
Join a thriving community of 45,000+ investors, including the top global asset managers managing over $13trn in assets.
or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 6-minute read)
Discussions
(Paid Plans Only)
Top 5%
Xinyao (Criss) Wang
HK/China Healthcare Analyst (ex-Fosun Pharma)
- Pre-IPO TransThera Sciences (Nanjing) - Insights on the Industry, the Business and the Concerns06 Oct 2021
- InnoCare Pharma Ltd (9969.HK) - Risk of Becoming Mediocre14 Sep 2021
- Innovent Biologics (1801.HK) - The Strength and the Concerns31 Aug 2021
- Pre-IPO Abbisko Cayman - It Still Takes Some Time for Commercialization21 Jul 2021
x